Novartis Pharmaceuticals UK Ltd

Recent awards

• SECUKINUMAB 300 mg Pre-filled Injection 1 Pen Pack
  8 September 2026 · £280,000
• REVOLADE (ELTROMBOPAG) TABLETS, 28 tablet
  17 June 2026 · £1,000,000
• TRAMETINIB 2MG TABLETS, 30 tablet, pack, PACK OF 1
  5 May 2026 · £270,000
• NHS National Framework Agreement for Omalizumab
  26 November 2025 · £87,433,000
• PRRT (Peptide Receptor Radionuclide Therapy)
  10 November 2025 · £1,820,000
• SECUKINUMAB 150 mg in 1mL Injection, SECUKINUMAB 300 mg in 2mL Solution for Injection
  10 November 2025 · £4,638,166
• MIDOSTAURIN 25MG CAPSULES
  13 August 2025 · £180,000
• ENHERTU (TRASTUZUMAB DERUXTECAN) 100MG POWDER FOR CONCENTRATE FOR SOLN FOR INFUSION VIAL
  13 August 2025 · £700,000
• NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
  31 July 2025 · £688,834,174
• NHS National Framework for Transition products (Axitinib and Eltrombopag)
  16 July 2025 · £52,385,000